Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Hepatitis
- Liver cancer
- Liver cirrhosis
- Nonalcoholic fatty liver disease
PART 06: Market landscape
- Global liver diseases therapeutics market
PART 07: Market segmentation by disease
- Hepatitis
- Liver cirrhosis
- Liver cancer
- Nonalcoholic fatty liver disease
PART 08: Global hepatitis therapeutics market
- Global hepatitis A therapeutics market
- Global hepatitis B therapeutics market
- Global hepatitis C therapeutics market
PART 09: Global liver cancer therapeutics market
PART 10: Global nonalcoholic fatty liver disease therapeutics market
PART 11: Global liver cirrhosis therapeutics market
PART 12: Market segmentation by type of molecule
- Biologics
- Small molecules
PART 13: Geographical segmentation
- Liver diseases therapeutics market in Americas
- Liver diseases therapeutics market in EMEA
- Liver diseases therapeutics market in APAC
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other and future prominent vendors
PART 20: Key vendor analysis
- F. Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
PART 21: Appendix
Part 22: Explore Technavio